results

Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results

March 20, 2026 13:30 ET  | Source: SANUWAVE Health, Inc. EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave…

2 months ago

Crescel Reports Positive Randomized Controlled Trial Results for Biobotanical Skin Renewal Cream in Rosacea

Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable TolerabilityMIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC,…

2 months ago

Cango Inc. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results

DALLAS, March 16, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG), a leading Bitcoin miner leveraging its global operations to develop an…

2 months ago

VitalHub Reports Fourth Quarter 2025 Results

Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 millionTotal Revenue up 52% YoY to $31.4 millionAdjusted EBITDA⁽¹⁾ up 47%…

2 months ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

March 12, 2026 21:03 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

2 months ago

VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results

TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has…

2 months ago

Hybrid Software Group PLC reports 2025 results with 17% increase in adjusted operating profit and 252% increase in net cash

PRESS RELEASE – REGULATED INFORMATION HYBRID SOFTWARE GROUP PLC REPORTS 2025 RESULTS WITH 17% INCREASE IN ADJUSTED OPERATING PROFIT AND…

2 months ago

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026 14:00 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE)…

3 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting…

3 months ago